May 20, 2008-Viralytics Limited (VLA) is pleased to advise that it has received a Notice of Allowance from the European Patent Office for its patent application covering the use of its family of 4 Coxsackie viruses for the treatment of all cancers bearing expression of the ICAM-1 molecule.
A Notice of Allowance is formal advice (publicly available) that the European Patent Office intends to issue a patent, which is expected to be granted in the next six months.
The granted European patent will provide Viralytics protection over the exclusive use in Europe of our family of Coxsackie A group viruses in the treatment of ICAM-1 bearing cancers until 2020.
The details can be read here.
No comments:
Post a Comment